SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
- Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies
- SOTIO to develop up to three next generation bioconjugates
- Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs
AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, enters licensing agreement with SOTIO Biotech (SOTIO), a clinical stage immuno-oncology company owned by PPF Group.
